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ABSTRACT  
Psychosis is a mental disorder characterized by a disconnection from reality. Psychosis is a group of disorder characterized by thought 
disorder, abnormal behaviour, defective cognition, delusion and hallucination. Adverse drug reaction is defined as any undesired or unintend ed 
effects of drugs treatment. According to the World Health Organization (WHO)- “adverse drug reaction (ADRs) has been defined one which is 
noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or modification of 
physiological function”. Adverse drug reactions are the most important causes of the mortality and morbidity. Antipsychotics are the most 
effective drugs which are used in the psychiatry in the maintenance therapy of mania, psychoses and schizophrenia. The antipsychotics drugs 
are chemically disparate but have the common property of alleviating the symptoms of organic as well as functional psychosis. But they also 
have a capacity to cause a wide range of potential adverse drug reactions that can lead to non-compliance that can impair quality of life, may 
cause the extra pyramidal symptoms which can lead to discontinuation of therapy and in extreme cases it may be fatal. Knowledge of 
assessment of ADRs due to different antipsychotics is necessary. It helps to choose to safe treatment and reduce the risk of occurrence of ADRs 
by the clinicians. ADR are often poorly identified and reported in day to day medical practice. As we collect more and more information about 
ADRs, we need an active surveillance system regarding identification and reporting of ADRs with antipsychotic drugs.  On many  review articles 
are read & ward round participation experiences we find that antipsychotic drugs can have shown a various kind of ADRs. Psychiatrist and 
clinical pharmacist are need to be made aware of these potentially fatal adverse effects associated with antipsychotic drugs via conduction of 
patients counseling regarding (drugs, disease, doses & side effects), quality-based seminars, published medical literature, conferences, learning 
programs and health care camps. 
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INTRODUCTION 
A psychosis is a mental disorder characterized by a 
disconnection from reality. A psychosis is a group of disorder 
characterized by thought disorder, abnormal behaviour, 
defective cognition, delusion and hallucination. Adverse drug 
reactions are the most important causes of the mortality and 
morbidity. The term psychosis refers to a severe form of 
mental disorder where there is gross disorganization of 
personality and severe impairment in social functions. These 
patients fail to realize what is real and what is not. 
Reasoning, judgment and insight are lost. Hallucinations and 
delusions may occur schizophrenia, delirium, dementia, 
mania, and depression are examples of psychosis1. 
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CLLASIFICATION OF PSYCHOTIC DISORDER: 
1. Acute and chronic organic brain syndromes 
(Cognitive Disorder):  
Such as delirium and dementia with psychotic features, 
some toxic or pathological basis can often be defined. 
Prominent features are confusions, disorientation, defective 
memory, disorganized thought and behaviour. 
2. Functional disorder:  
No underling cause can be defined, memory and orientation 
are mostly retained but emotion, thought, reasoning and 
behaviour are seriously altered. 
i. Schizophrenia (Split Mind):  Schizophrenia is 
characterized by delusion, hallucination and lack of 
insight. Acute schizophrenia may also present with 
disturbed behaviour, disturbed thinking, or with 
insidious social withdrawal and other so called 
negative symptoms and less obvious delusion and 
hallucination.  
 There is no anatomical and pathological defect in the 
brain. 
 Psychosis is due to functional impairment of the brain. 
 The cognition is not impaired. 
Clinical Symptoms:  
The symptoms of schizophrenia are generally organized into 
two main domains: positive and negative (Table 1). Positive 
symptoms are usually what the public perceives when 
thinking about schizophrenia: hallucinations, delusions, and 
disorganization. Hallucinations can affect any of the five 
senses, but auditory are the most common. Delusions are 
fixed false beliefs that are persistent despite evidence to the 
contrary. Delusional subtypes include persecutory, 
erotomaniac (e.g., delusion of love), delusions of grandeur 
(having special abilities), or somatic (i.e., delusion of being 
pregnant in context of negative pregnancy tests). 
Disorganization can manifest in the patient’s speech, thought 
patterns, or behaviours. Some examples of disorganized 
speech can include made-up words (neologisms), rhyming 
words (clang speech), speaking words in a sentence in 
incorrect order (word salad), and repeating words said to 
them (echolalia). Examples of disorganized behaviours can 
include repeating the same activity needlessly 
(perseveration), repeating someone else’s actions 
(echopraxia), dressing oddly for the setting or season of the 
year (wearing winter clothes in summer), or other odd 
behaviours based upon the setting the patient is in. Negative 
symptoms of schizophrenia include apathy, avolition, 
blunted affect, and poverty of speech. A decreased ability to 
experience pleasure (known as anhedonia) and social 
withdrawal can lead to significant functional impairment, 
even when positive symptoms are relatively absent in a 
patient. During acute episodes, positive symptoms may 
predominate, whereas over the long term it may be negative 
symptoms that are more troubling and disabling to a patient. 
A third domain of cognitive symptoms can also present in 
schizophrenia. Symptoms include concrete thinking, 
inattention, problems with memory, learning and executive 
function, as well as conceptual disorganization. When these 
cognitive symptoms are combined with negative symptoms 
over the patient’s lifespan, significant impairment in function 
may result. Comorbid depression is also common in 
schizophrenia and can be difficult to treat, and symptoms can 
be predictive of relapse. Depressive symptoms may be 
overlooked in the face of overwhelming positive symptoms 
or confused with negative symptoms3. 
 
Table-1 Positive and Negative Symptoms of Schizophrenia 
S no. Positive Symptoms Negative Symptoms 
1. Hallucinations (auditory, visual, or other senses) Diminished emotional expression (body language) 
2. Delusions (persecutory, paranoid, grandiose, etc.) Avolition/psychomotor retardation 
3. Disorganized thinking/speech Alogia (decreased speech) 
4. Grossly disorganized or abnormal motor behaviour 
(including catatonia) 
Anhedonia (decreased ability to feel pleasure) 
5. Unusual behaviour Asociality (lack of socialization) 
6. Combativeness, agitation, and hostility Affective flattening 
7. Ideas of reference Social Withdrawal 
 
ii. Paranoid States:  Paranoid States with marked 
persecutory or other kinds of fixed delusion (false 
beliefs) and loss of insight in to the abnormality. About 
one third of patients suffers from this type and are 
characterized by presence of delusion and 
hallucinations. However, there is no thought disorder 
and no incoherent thinking. 
iii. Mood (affective) Disorder: Affective disorders are a 
set of the psychiatric disease, also called as mood 
disorder. The primary symptoms is change is mood 
state, may manifest as: 
 Bipolar disorder (mania & depression) 
Mania: elation and irritable mood, reduced sleep, 
hyperactivity, uncontrollable thought and speech, may be 
associated with reckless or violent behaviour. 
Depression: sadness, loss of interest and pleasure, 
worthlessness, guilt, physical and mental slowing, 
melancholia, self-destructive ideation3. 
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Different types of depression: 
S. No. Type of depression Characteristic 
1. Persistent depressive disorder Patients have depressed mood for at least two years. 
2. Bipolar disorder Mood of a person fluctuates from depression to mania. 
3. Seational affective disorder Mood is affected by season and there is a development of 
depression during the winter. 
4. Psychotic depression Patients exhibit signs of psychosis along with depression. 
5. Perinatal depression Woman experience symptoms of major depression during 
pregnancy or after delivery. 
 
Neurosis on the other hand, is a less severe form of mental 
disorder with minor impairment in social and personality 
function. Sense of reality, reasoning and insight are retained. 
Hallucinations and delusions are absent. 
Generalized anxiety disorders, conversion and dissociative 
disorders, obsessive compulsive disorders, and phobic 
disorders are examples of neurosis.  
a. Anxiety: An unpleasant emotional state associated 
with uneasiness, worry, tension and concern for the 
future. 
b. Phobic states: Fear of the unknown or of some specific 
objectives, person and situations. 
c.  Obsessive compulsive disorder (OCD):  
Obsession:  
OCD is an anxiety disorder in which people have unwanted 
and repeated thoughts, feelings, ideas, sensation (obsession). 
eg 
  Repetitive thought (eg feeling contaminated after 
touching, an object, doubting weather the store was 
turned off.) 
 Repetitive images (eg recurrent sexually explicit punts) 
 Repetitive hand washing  
Compulsion:  
Normal repetitive behaviour that feature in everyday life 
may include bedtime routine, religious, practice and learning 
a new skill. Behaviour that makes them feels down to do 
something (compulsions). eg. 
 Washing and cleaning including constant hand 
washing. 
 Checking including, checking body parts. 
 Repeating including rereading and repeating routine 
activities like getting up from a chair. 
 Mental compulsion, including praying to present harm 
and mentally reviewing events. 
Limited abnormality of thought or behaviour, recurrent 
intrusive thoughts or ritual-like behaviours which the 
patients realize are abnormal or stupid but is not able to 
overcome even a voluntary effort. The obsessions generate 
considerable anxiety and distress.  
d. Reactive depression: Due to physical illness, loss, 
blow to self-esteem or bereavement, but excessive or 
disproportionate. 
e. Post-traumatic stress disorder: varied symptoms 
following distressing experiences like war, riots, 
earthquakes etc. 
f. Hysterical: Dramatic symptoms resembling serious 
physical illness, but situational, and always in the 
presence of other, the patients do not feign but actually 
undergoes the symptoms, though the basis is only 
psychic and not physical1.       
The terms ‘organic’ vs ‘functional’ is a dichotomy still alive in 
psychiatric vocabulary. Antipsychotics are the most effective 
drugs which are used in the psychiatry in the maintenance 
therapy of mania, psychoses and schizophrenia2. 
Antipsychotics are the most effective drugs which are used in 
the psychiatry in the maintenance therapy of mania, 
psychoses and schizophrenia3. The antipsychotics drugs are 
chemically disparate but have the common property of 
alleviating the symptoms of organic as well as functional 
psychosis. But they also have a capacity to cause a wide 
range of potential adverse drug reactions that can lead to 
non-compliance that can impair quality of life, may cause the 
extra pyramidal symptoms (EPS) which can lead to 
discontinuation of therapy and in extreme cases it may be 
fatal4,5. Antipsychotics drugs have a broad spectrum of 
therapeutic effect in clinical practice and are generally safer 
agents. Adverse effects are augmentation of many 
pharmacological actions of these drugs such as autonomic 
nervous system, central, cardiovascular, and endocrine 
system6,7,8. 
Knowledge of assessment of ADRs due to different 
antipsychotics is necessary. It helps to choose to safe 
treatment and reduce the risk of occurrence of ADRs by the 
Psychiatrist. The second generations of antipsychotic drugs 
are differed from the first generation as they have a low risk 
of adverse reactions such as extra pyramidal symptoms 
(EPS) and also reduce the positive and negative symptoms of 
schizophrenia. Besides low tendency of exhibiting an Extra 
pyramidal symptoms (EPS), second generation 
antipsychotics exhibit their own spectrum of adverse effects 
including hypotension, seizures, weight gain, increased risk 
of diabetes mellitus, hyperlipidaemias. These ADRs are not 
only common but also have a high rate of preventability. The 
selection of medicines should be targeted for quality 
improvement patient healthcare system. It can be done by 
the data use of frequency, severity, probability and 
preventability. After getting all the information of high-risk 
drugs through analysis may have significant impact on 
reducing the ADRs9,10.  
Hence, an attempt has been made in this article exhibit an 
updated analysis of ADRs which are caused by antipsychotics 
drug and how to manage the ADRs in general outlook and 
what are the future outcomes in the management of adverse 
drug reaction11.  
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CLASSIFICATION OF ANTIPSYCHOTIC DRUGS  
First-Generation Antipsychotics 
• The first-generation antipsychotic drugs (also called 
conventional, typical, or traditional antipsychotics) are 
competitive inhibitors at a variety of receptors, but their 
antipsychotic effects reflect competitive blocking of D2 
dopamine receptors. First-generation antipsychotics are 
more likely to be associated with movement disorders, 
particularly for drugs that bind tightly to dopaminergic 
neuroreceptors, such as haloperidol. 
– First-Generation Antipsychotics (Typical) (low 
potency) 
 Chlorpromazine (100-800mg/day) 
 Triflupromazine (50-200mg/day) 
 Thioridazine (100-400mg/day) 
– First-Generation Antipsychotics (Typical) (high 
potency) 
• Fluphenazine (1-10mg/day) 
 Haloperidol (5-20mg/day) 
, Pimozide (2-6mg/day) 
, Thiothixene (5-60mg/day) 
Second-Generation Antipsychotic Drugs (Atypical) 
• The second-generation antipsychotic drugs (also referred 
to as “atypical” antipsychotics) have fewer extrapyramidal 
symptoms (EPS) than the first-generation agents but are 
associated with a higher risk of metabolic side effects, such 
as diabetes, hypercholesterolemia, and weight gain. The 
second-generation drugs appear to owe their unique activity 
to blockade of both serotonin and dopamine receptors. 
Aripiprazole (10-30mg/day),  
Clozapine (100-300mg/day),  
Molindone (50-70mg/day),  
Olanzapine(2.5-20mg/day),  
Quetiapine (50-400mg/day), 
Risperidone (2-8mg/day),  
MECHANISM OF ACTION (FGAs) 
Dopamine Hypothesis: The dopamine hypothesis states 
that antipsychotics reduce psychotic symptoms by 
decreasing dopamine activity. It was originally proposed by 
Arvid Carlsson from Sweden and other basic scientists based 
on the observation that haloperidol and chlorpromazine 
raised the levels of dopamine metabolites in dopamine-rich 
areas of mouse brain. These drugs had inconsistent effects on 
other neurotransmitters. They interpreted these findings as 
indicating that these two agents were acting as dopamine 
antagonists and that self-regulating systems were 
compensating by increasing dopamine production. Other 
investigators noted that FGAs inhibit the activation and 
stereotypical behaviours of rodents that are induced by 
amphetamine. This effect has been found to be a reasonably 
reliable predictor of antipsychotics activity in patients. 
Moreover, the dose-response relationships in animals 
provide information about the likely clinical dosage range for 
patients. These behaviours are thought to be mediated by 
dopamine and have been used as screening devices to 
identify compounds that are likely to have clinical efficacy as 
antipsychotics. Other evidence supporting a role of 
dopamine in psychosis comes from the observation that all 
drugs-at least to this date-capable of reducing psychosis are 
also dopamine antagonists, including partial dopamine 
agonists. Moreover, agents that are associated with increased 
dopamine activity such as amphetamine, methylphenidate, 
or cocaine tend to increase dopamine neurotransmission and 
also tend to worsen patients with schizophrenia who are in 
clinically unstable conditions 4,7,8. 
According to the dopamine theory of schizophrenia, positive 
symptoms are the result of an over activity in the mesolimbic 
dopamine pathway. This is in part based on the observation 
that drugs that increase dopaminergic availability (L-DOPA, 
cocaine, amphetamines) can trigger psychotomimetic effects 
in individuals not affected by schizophrenia first-generation 
antipsychotics are D2 antagonists. As a result, they reduce 
dopaminergic neurotransmission in the four dopamine 
pathways9. 
Effects of First-Generation Antipsychotics on the Four 
Dopamine Pathways (Shown Table 2) 
1. Nigrostriatal Pathway: Extrapyramidal Symptoms: 
In which fibres originate from the A9 region of the pars 
compacta and project rostrally to become widely 
distributed in the caudate nucleus and the putamen. 
One of the major functions of dopamine in nigrostriatal 
pathway is movements. Antagonism of D2 receptors in 
the nigrostriatal pathway is associated with increased 
risk of extrapyramidal symptoms 4,8. 
2. Tuberoinfundibular Pathway: Hyperprolactinemia: 
This originates in the arcuate nucleus of the 
hypothalamus and projects to the median eminence. 
Dopamine acts asprolactin-inhibiting factor or it 
synonyms with prolactin inhibiting factor in 
tuberoinfundibular pathways. D2 blockade in this path 
way increases prolactin levels by promoting its release 
in the pituitary gland causing hyperprolactinemia 4,7. 
3. Mesocortical Pathway: In which the dopaminergic 
fibbers also arise from the A10 region (the ventral 
tegmental area) and project to the frontal cortex and 
sept hippocampal regions. Schizophrenia 
pathophysiology suggests that a dysfunction of 
mesocortical pathway is associated with cognitive 
impairments and disturbances of emotions and affect 
(negative symptoms). Blockade of the mesocortical 
pathway by high doses of first-generation 
antipsychotics can induce secondary negative 
symptoms and cognitive effects 4,9. 
4. Mesolimbic Pathway: (Antipsychotic Effects) Where 
the dopaminergic projections originate in the ventral 
tegmental area, the A10 region, and then spread to the 
amygdala, pyriform cortex, lateral septal nuclei and the 
nucleus accumbens. Over activity of mesolimbic 
dopamine pathway is thought to be involved in the 
pathophysiology of positive symptoms of 
schizophrenia. Blockade of D2 receptors in the 
mesolimbic pathway has been proposed as a possible 
mechanism of antipsychotic action of first-generation 
agents 4,10. 
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TABLE 2 Clinical Effects of Receptor Antagonism by Antipsychotics 
S. no. Receptor (Subtype) Clinical Effect of Antagonism 
1. Dopamine (D2) 
 
Mesolimbic pathway (basal ganglia)—treatment of positive symptoms 
Mesocortical pathway (prefrontal cortex)—may worsen negative symptoms 
Nigrostriatal pathway (substantia nigra)—extrapyramidal symptoms (EPS) 
Tuberoinfundibular pathway (hypothalamus–anterior pituitary)—increased 
prolactin release 
2. Serotonin (5-HT2a) 
 
Treatment of negative symptoms;  
increased dopamine release in prefrontal cortex;  
may reduce mesolimbic dopamine release 
3. Serotonin (5-HT2c) Implicated in antipsychotic-associated weight gain 
4. Muscarinic (μ1) Anticholinergic side effects (dry mouth, constipation, urinary retention, blurred vision, 
hot/dry skin, memory impairment); sedation 
5. Histamine (H1) Increased appetite, sedation 
6. Alpha (α1) Orthostatic hypotension 
 
MECHANISM OF ACTION (SGAs) 
Most SGAs differ from older medications pharmacologically 
in that serotonin 5HT2 receptor binding exceeds their 
affinity for dopamine D2 receptors, whereas in FGAs this is 
generally not the case. Largely for that reason, 5HT2 activity 
has been suggested as one basis for the lower overall risk of 
extrapyramidal side effects (EPS) with the atypical drugs 
compared with FGAs. Other aspects of SGA pharmacology 
that correlate with reduced risk of EPS include "loose" D2 
receptor binding with rapid dissociation rates and 
preferential binding of drugs to receptors in limbic and 
cortical brain regions rather than striatal areas. None of 
these hypotheses has been fully confirmed, and the most 
important message for the clinician is that the pharmacology 
of these drugs is complex and likely to result in some 
variability of side effect risk and pharmacokinetics from 
patient to patient6. 
PHARMACOKINETICS (ADME) OF ANTIPSYCHOTIC 
DRUGS  
Absorption 
Mostly, all the antipsychotics drugs are readily but 
incompletely absorbed. Many drugs undergo first pass 
metabolism. The oral administration of Chlorpromazine & 
Thioridazine have systemic availability of 25-35%, whereas 
Haloperidol systemic availability of about 65%. In general, 
the FGAs are well absorbed when they are administered 
orally or parentally. As with most drugs, oral administration 
leads to less predictable absorption than parenteral 
administration. Liquid concentrates are absorbed slightly 
more rapidly than pills. Plasma concentrations of the drugs 
usually reach peak levels 1 to 4 hours after ingestion and 30 
to 60 minutes after intramuscular (IM) administration. In 
general, IM preparations reach their peak concentrations 
sooner than oral drugs and as a result have an earlier onset 
of action. For example, IM administration of most 
antipsychotics results in peak plasma levels in about 30 
minutes with clinical effects emerging within 15 to 30 
minutes 3,4. 
Half-Lives and Steady State 
Antipsychotics usually reach steady state in about three to 
five half-lives. Thus, steady state levels for chlorpromazine, 
haloperidol, and most other FGAs are reached in about 3 to 5 
days since their half-lives are about 24 hours 4. 
Distribution 
Antipsychotic drugs are highly lipid soluble & protein bound 
i.e., 92 to 99%. They also have a large volume of distribution 
(i.e., >7L/Kg). They have long duration of action than would 
be estimated from their plasma half-lives. Symptoms of 
psychoses will be reoccurrence in 6 months after the 
discontinuation of treatment4.  
Bioavailability 
The bioavailability (that is, the amount of drug reaching the 
systemic circulation) is substantially greater-as much as 
tenfold when FGAs are administered parenterally. Most FGAs 
are highly protein bound. For example, more than 90 percent 
of drugs such as fluphenazine and haloperidol is bound to 
plasma protein. The remaining unbound portion is the drug 
that is available for passing through the blood-brain barrier. 
In theory, conditions that alter the amount of plasma protein 
such as malnutrition will also alter the amount of 
bioavailable antipsychotic drug. This is potentially important 
for drugs that are protein bound for 98 percent or more 4. 
Metabolism and Elimination 
Antipsychotics drugs are metabolized by the oxidation, 
demethylation, catalysed by liver microsomal CYP-P450 
enzymes, CYP2D6, CYP1A2, CYP3A4. The elimination t1/2 is 
variable, but mostly is in the range of 18-30 hrs. The 
metabolites are excreted in urine & bile weeks after the 
discontinuing of treatment. The broad spectrum of 
pharmacokinetics of neuroleptics is similar. Most FGAs are 
metabolized by the cytochrome P450 2D6 and P450 3A 
subfamilies in the liver. Since these same isoenzymes also 
metabolize a number of drugs that are commonly combined 
with antipsychotics, a number of important drug–drug 
interactions are possible the systemic clearance of FGAs is 
high as the result of a high hepatic extraction ratio. As a 
result, only negligible amounts of the unchanged drug are 
excreted by the kidneys. Phenothiazines, thioxanthenes, and 
their metabolites are excreted in the urine and the faeces14. 
(Show Table 3) 
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Pharmacokinetic Of Selected First-Generation Antipsychotics 
Table 3. Pharmacokinetics of Selected antipsychotics. 
Drug Bioavailability 
(%) 
Protein binding 
(%) 
t1/2 (hrs) Cp 12 hrs Post dose (ng/ml) 
Chlorpromazine 10-33 90-95 8-35 100-300 
Thioridazine 25-33 99 9-30 200-800 
Perphenazine 25 90-95 8-21 0.5-5.0 
Fluphenazine 20-50 90-95 14-24 0.2-3.0 
Haloperidol 40-70 92 36 2-18 
Thiothixene 50 90-95 34 1-5 
Cp-Concentration in plasma after 12 hours. 
 
PHARMACODYNAMICS OF ANTIPSYCHOTIC DRUGS  
Mechanism of action of all the antipsychotics in the brain is 
D2 receptors antagonism that has given rise to the 
hypothesis that schizophrenia and other positive and 
negative symptoms. Positive symptoms may occur by the 
dysregulation of dopaminergic circuits with excess 
dopaminergic activity in mesolimbic pathway and negative 
symptoms due to the dopaminergic signalling in the 
mesocortical pathways. The affirmation for the dopamine 
hypothesis comes from not only the potency of D2 receptor 
antagonism, but also the effect of D2 agonists such as 
amphetamine in precipitating psychosis and the effect of 
dopamine depleting drugs such as reserpine in reducing 
psychotic symptoms.15  
For Schizophrenia, antipsychotic drugs are the cornerstone 
of the pharmacological treatment such as chlorpromazine 
which is introduced in 1952 as a first-generation 
antipsychotic drug. The early antipsychotic drugs are also 
come in the market as Chlorpromazine, Haloperidol, 
Fluphenazine are referred to as first generation 
antipsychotics. These drugs are affecting in relieving positive 
symptoms but also exhibit a extra pyramidal symptoms, 
tardive dyskinesia. Because of limitation of these agents may 
lead to introduced of newer antipsychotics drugs in 1990 
such as resperidone, olanzepine, quetiapine, etc. Newer 
antipsychotics are now termed as second-generation 
antipsychotic drugs which have a low risk of causing a extra 
pyramidal symptoms, tardive dyskinesia and also have 
frequency of producing some adverse drug reactions such as 
weight gain, metabolic changes and associated 
cardiovascular consequences.16,17  
The first-generation antipsychotics are effective in the 
treatment of Schizophrenia but also have tendency to exhibit 
extra pyramidal symptoms and lead to tardive dyskinesia. 
However, clozapine withdrawal from the market by 
manufacturers because it have ability to produce 
agranulocytosis but later it is reintroduced in the market 
with strict regulations as white blood cell count follow up 
and other investigations18,19 All the antipsychotics are 
effective by binding on D2/D3 receptors in the ventral 
straitum.20 Both first and second generation antipsychotics is 
associated with a clear, dose-dependent risk of seizure 
provocation. The risk of seizure provocation is high with first 
generation antipsychotic drugs as compared to second 
generation antipsychotic drugs. The risk of seizure seems 
higher for clozapine and lowest for Resperidone.21 The 
majority of adverse effects of antipsychotic drugs are 
extensions of their pharmacological action, also these are 
some adverse effects.22 In general, antipsychotics drug have 
better mainstay in the treatment of psychoses and other 
mental problems but also have tendency to cause adverse 
effects23. 
SIDE EFFECTS & ADRs of ANTIPSYCHOTICS DRUGS 
Adverse drug reaction (ADRs) is defined as any undesired 
or unintended effects of drugs treatment. According to the 
World Health Organization (WHO)- “adverse drug reaction 
(ADRs) has been defined one which is noxious and 
unintended, and which occurs at doses normally used in man 
for prophylaxis, diagnosis, or therapy of disease, or 
modification of physiological function”1.   
Adverse drug events (ADEs) is an injury resulting from the 
use of the drugs. Under this definition, the term ADE includes 
harm caused by the drugs (ADRs & overdoses) and harm 
form the use of the drugs (including dose reduction and 
discontinuous of drug therapy). ADE may results form 
medication errors but most do not2. 
 
  
           
 
 
 
 
Figure 1- Relationship between ADRs & ADEs 
                   
Treatment with antipsychotic drugs, whether typical or 
atypical agents, is associated with various adverse effects, 
including acute EPS (dystonia, parkinsonism and akathisia), 
chronic EPS (tardive dyskinesia), neuroleptic malignant 
syndrome, weight gain, glucose intolerance (diabetes 
mellitus [DM]), metabolic syndrome and elevation of plasma 
prolactin levels. Several of these side effects are known to be 
related to distinct pharmacological profiles of the 
antipsychotic agents. For example, parkinsonism, tardive 
dyskinesia, neuroleptic malignant syndrome sand 
ADEs 
ADRs 
Not need to have a causal relationship 
Causal relationship is suspected / 
established 
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hyperprolactinemia are considered to be a result of acute or 
chronic blockade of DA receptors, while histamine-H1 and 5-
HT2Creceptors may contribute to antipsychotic-induced 
weight gain.1,3 These are the adverse drug reactions 
which is associated by antipsychotic drugs are as 
follows- 
A. Central Nervous System 
1. Extrapyramidal System 
a. Dystonia 
• Dystonia are prolonged tonic muscle contractions, 
(occurring usually within 24–96 hours of dosage initiation or 
dosage increase); they may be life threatening (eg, 
pharyngeal-laryngeal dystonia). Other dystonia are trismus, 
gloss spasm, tongue protrusion, blepharospasm, oculogyric 
crisis, torticollis, and retro Collis. They occur primarily with 
FGAs. Risk factors include younger patients (especially male) 
and use of high-potency agents and high dose. 
• Treatment includes IM or IV anticholinergics or 
benzodiazepines. Benztropine mesylate, 2 mg, or 
diphenhydramine, 50 mg, may be given IM or IV, or 
diazepam, 5 to 10 mg slow IV push, or lorazepam, 1 to 2 mg 
IM, may be given. Relief usually occurs within 15 to 20 
minutes of IM injection or 5 minutes of IV administration. 
• Prophylactic anticholinergic medications (but not 
amantadine) are reasonable when using high-potency FGAs 
(eg, haloperidol and fluphenazine), in young men, and in 
patients with a prior dystonia. Dystonia can be minimized by 
using lower initial doses of FGAs and by using SGAs instead 
of FGAs. 
b. Akathisia 
• Symptoms include subjective complaints (feelings of inner 
restlessness) and/or objective symptoms (pacing, shifting, 
shuffling, or tapping feet). 
• Treatment with anticholinergics is disappointing. 
Reduction in antipsychotic dose may be the best 
intervention. Alternatively, switch to an SGA, although 
akathisia occasionally occurs with the SGAs. Quetiapine and 
clozapine appear to have the lowest risk. Benzodiazepines 
may be used, but not in patients with a history of substance 
abuse. Propranolol (up to 160 mg/day), nadolol (up to 80 
mg/day), and metoprolol (up to 100 mg/day) are reported to 
be effective. 
c. Pseudo parkinsonism 
• Patients with pseudo Parkinsonism may have any of four 
cardinal symptoms: 
✓ Akinesia, bradykinesia, or decreased motor activity, 
including mask-like facial expression, micrographia, slowed 
speech, and decreased arm swing 
✓ Tremor—predominantly at rest; decreasing with 
movement 
✓ Rigidity—stiffness; cogwheel rigidity is seen as the 
patient’s limbs yield in jerky, ratchet-like fashion when 
moved passively by the examiner. 
✓ Postural abnormalities—stooped, unstable posture and 
slow, shuffling, or festinating Gait. 
• Risk factors—FGAs (especially in high dose), increasing 
age, and possibly female gender. 
• Accessory symptoms—seborrhea, sialorrhea, 
hyperhidrosis, fatigue, weakness, dysphagia, and dysarthria. 
• The onset of symptoms is usually 1 to 2 weeks after 
initiation of antipsychotic therapy or dose increase. The risk 
of pseudo parkinsonism with SGAs is low except with 
risperidone in doses greater than 6 mg/day. 
• Benztropine has a half-life that allows once- to twice-daily 
dosing. Typical dosing is 1 to 2 mg twice daily up to a 
maximum of 8 mg daily. Trihexyphenidyl, diphenhydramine, 
and biperiden usually require three-times-daily dosing. 
Diphenhydramine produces more sedation. All of the 
anticholinergics have been abused for euphoriant effects. 
• Amantadine is as efficacious as anticholinergics with less 
effect on memory. 
• Attempt to taper and discontinue these agents 6 weeks to 3 
months after symptoms resolve. 
d. Tardive Dyskinesia 
• Tardive Dyskinesia (TD) is characterized by abnormal 
involuntary movements occurring with chronic antipsychotic 
therapy. 
• The classic presentation is buccolingual-masticatory (BLM) 
or orofacial movements. Symptoms may become severe 
enough to interfere with chewing, wearing dentures, speech, 
respiration, or swallowing. Facial movements include 
frequent blinking, brow arching, grimacing, upward 
deviation of the eyes, and lip smacking. Restless choreiform 
and athetotic movements of the limbs occur in later stages. 
Movements may worsen with stress, decrease with sedation, 
and disappear with sleep. 
• Screen at baseline and at least quarterly using the 
Abnormal Involuntary Movement Scale (AIMS) and the 
Dyskinesia Identification System: 
1 Condensed User Scale (DISCUS) to detect TD. 
 Dosage reduction or discontinuation may reduce 
symptoms, and some patients may have complete 
disappearance of symptoms if implemented early in the 
course of TD. 
 Prevention of TD- (1) use SGAs as first-line agents;  
2 Use the DISCUS or other scales to assess for early signs 
of TD at least quarterly; and  
3 Discontinue antipsychotics or switch to SGAs at the 
earliest symptoms of TD, if possible. 
• Risk factors for TD—duration of antipsychotic therapy, 
higher dose, possibly cumulative dose, increasing age, 
occurrence of acute extrapyramidal symptoms, poor 
antipsychotic response, and diagnosis of organic mental 
disorder, diabetes mellitus, mood disorders, and possibly 
female gender. 
• Switching to clozapine is a first-line strategy in patients 
with moderate to severe dyskinesias24,25,26,27. 
B. Anti-cholinergic effects  
Anti-cholinergic effects include constipation, urinary 
retention, dry mouth, blurred vision. These effects are 
common with low potency first generation antipsychotics 
and clozapine. Anticholinergic side effects, most likely to 
occur with low potency FGA, clozapine, and olanzapine, 
include impaired memory, dry mouth, constipation, 
tachycardia, blurred vision, inhibition of ejaculation, and 
urinary retention. Elderly patients are especially sensitive to 
these side effects. Dry mouth can be managed with 
increased intake of fluids, oral lubricants (Xerolube), ice 
chips, or the use of sugarless chewing gum or hard candy. 
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Constipation can be treated with increases in exercise, fluid, 
and dietary fiber intake.28,29,30 
C. Hyperprolactinemia  
It occurs mostly within a few weeks of beginning of 
treatment or increasing the dosage but can also arise after 
long-term stable use. It is a common with the use of any 
first-generation antipsychotic drugs as well as second 
generation antipsychotic drugs such as Risperidone and is 
dose dependent. An increase in prolactin levels may cause 
by blocking of dopamine in hypothalamus and it results, 
galactorrhoea in men. Hence, physicians routinely measure 
the serum prolactin levels. 31,32 
D. Cardiovascular  
All antipsychotic may cause ECG changes such as prolonged 
QT interval and orthostatic hypotension. Orthostatic 
hypotension occur with the low-potency first generation 
antipsychotic drugs such as Chlorpromazine, thioridazine 
and with second generation antipsychotic drugs such as 
Clozapine, Resperidone, Olanzepine, Quetiapine. 
Antipsychotics most likely to cause ECG changes are low 
potency first generation antipsychotic drug such as 
thioridazine and the second-generation antipsychotic drug 
such as Ziprasidone.33,34,35,36 
E. Sexual Dysfunction  
Sexual dysfunction refers to as reduction in desire or libido, 
diminished arousal, decline in the frequency of intercourse. 
It is very common and up to 49% of patients taking 
antipsychotic drugs report problems with sexual 
dysfunction, a distressing adverse effect that can lead to poor 
medication adherence. Both FGAs and SGAs drugs can impair 
arousal and orgasm in men and women. Galactorrhea in 
women and men also gynecomastia in men are more 
common with second generation antipsychotics and with 
resperidone and can be dos e related.37,38,39  
F. Weight Gain  
The common adverse effect of antipsychotic drugs are 
weight gain which can be rapidly increase and difficult to 
control. It doesn’t dose-dependent and substantially 
significant side effect of antipsychotic drugs and mainly 
reported in adults and children. Olanzepine and Clozapine 
may cause more weight gain as compared to other atypical 
antipsychotic drugs such as >7% of the baseline bodyweight 
in 40% or more of patients. It can also induce 
cardiovascular and cerebrovascular morbidity and 
mortality reduced quality of life and poor drug compliance. 
The first-generation antipsychotic drugs such as 
Chlorpromazine and thioridazine cause high risk of weight 
gain but risk is greatest with use of second-generation 
antipsychotic drugs such as Clozapine and Olanzepine. 
Antipsychotic drugs such as Quetiapine, Resperidone, 
Paliperidone, Sertindole, Zotepine have intermediate risk of 
weight gain. These are the factors which are responsible for 
the risk of weight gain due to antipsychotic drugs at re-
demographic variables, treatment settings, illness 
characteristics, history and current treatment with 
antipsychotics and other drugs etc.40,41,42  
G. Neuroleptic Malignant Syndrome  
A life-threatening reaction may cause by the use of 
antipsychotic drugs but it is rare. It can be initiated within 
first week of treatment of antipsychotics but can develop at 
any time. NMS is characterized by labile blood pressure, 
tachypnoea, tachycardia, sialorrhea, and flushing, skin 
pallor. The idiosyncratic reactions to antipsychotic drugs 
include cardiopulmonary arrest, aspiration pneumonias, 
myoglobinuric renal failure with special reference to 
Clozapine. Up to 9% of total death rate was reported and 
out of 177 cases 20% of cases of NMS with patients aged 18 
years or younger were reported as serious adverse drug 
reactions.43,44,45 
H. Sedation And Cognition 
• Administration of most or the entire daily dose at bedtime 
can decrease daytime sedation and may eliminate the need 
for hypnotics. 
• Compared to FGAs, the SGAs have shown cognitive benefits. 
However, the CATIE trial showed no difference in cognitive 
improvement between SGAs and the FGA perphenazine1,2. 
I. Seizures 
• All patients treated with antipsychotics have an increased 
risk of seizures. The highest risk for antipsychotic-induced 
seizures is with the use of chlorpromazine or clozapine. 
Seizures are more likely with initiation of treatment and with 
higher doses and rapid dose increases. 
• When an isolated seizure occurs, a dosage decrease is 
recommended, and anticonvulsant therapy is usually not 
recommended. 
• If a change in antipsychotic therapy is required, 
risperidone, thioridazine, haloperidol, pimozide, 
trifluoperazine, and fluphenazine may be considered.1
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J. Other Side effects of Antipsychotic Drugs  
Some of the ADRs are very common but discussion and 
reporting are very little such as constipation, fever, 
hypersalivation, nausea, colitis, delirium, eosinophilia, heat 
stroke, hepatic failure, pancreatitis, nocturnal enuresis. 
Clozapine is the most common agent which is responsible for 
the constipation. It can be severe and may lead to serious 
problems such as ileus, bowel occlusion and sometimes may 
be death. 1,2 
Implications and Management  
The burden of ADRs with the use of psychiatric drugs varies 
among studies. The range of implicated agents is diverse but 
antidepressant and antipsychotics drugs are most commonly 
associated with ADRs. These are the key points which is 
helpful in management of ADRs and facilitating the well-
being of patients46,47,48 –  
a. Clinicians have to able aware about all the ADRs which 
are associated from antipsychotic drugs.  
b. The need to balance the potential risks with expected 
benefits has to be kept in mind by clinicians, Treatment 
is individualized as per patient basis such as diagnosis, 
age, physical status, other factors like co-morbid 
conditions, other history of medications, patient past 
response, nutritional status and so on.  
c. Clinicians should be keep in mind that medication 
prescriptions should be accompanied by appropriate 
device.  
d. When a patient on antipsychotic drugs, frequent 
assessment of metabolic parameters, ECG have to done.  
e. Finally, keep in mind a current literature of patients 
will help a clinician better formulate a treatment plan, 
anticipate potential problem, and avoid them.  
ROLE OF THE CLINICAL PHARMACIST 
Since therapeutic compliance rates are so low and side 
effects are varied, clinical pharmacists have an important 
role to play in the management of schizophrenia. A recent 
study showed that 74% of schizophrenic patients 
discontinued their medication (medical adherence) within 
1.5 years.52 The likelihood that a patient will develop a 
particular side effect depends upon the patient’s 
vulnerability as well as the dose being administered and 
other co-administered medications.51 Clinical Pharmacists 
can monitor side effects and hence improve compliance by 
inquiring about positive and negative symptoms when the 
patient refills prescriptions, and communicate regularly with 
the patient’s other health care professionals about changes in 
symptoms. In addition to ensuring the correct dosing of 
appropriate drugs, clinical pharmacists are key in guiding 
patients about where they can obtain further help (e.g., 
through individual or group therapy). 
While existing antipsychotic medications are often effective 
for treating positive symptoms, they have little impact on 
negative symptoms and cognitive deficits. Therefore, there is 
a need to develop drugs that will allow for patient-specific 
treatment of symptoms. For example, lurasidone is a newer 
SGA that may be effective for cognitive symptoms. 
Additionally, while the newer therapies have addressed the 
issue of motor side effects, safety, and tolerability, there are 
increased concerns regarding weight gain and metabolic 
abnormalities.53 
 
 
General Procedures for Manage ADRs-  
i) Lower the dose – When a antipsychotic drug provided 
benefit to the patients the ADR is also occur but it is dose-
dependent. So, the lowest dose is prescribed to the patients 
for achieving treatment goals.  
ii) Switch to an antipsychotic drug – It can be relevant 
when the dosage adjustment cannot be proven beneficial for 
the patients and addressed a life- threatening or fatal.  
iii) Prescribed a non- pharmacologic intervention – It 
proven effective when weight gain and related lipid 
abnormality was addressed so, the diet and exercise 
programs are effective.  
iv) Treat with a concomitant medication – These are used 
for reducing the ADRs which is associated by antipsychotic 
drugs but they also have own adverse effects. Hence, few 
concomitant medication approaches are supported by 
evidence from randomized controlled trials49,50. 
CONCLUSION  
Occurrence of ADR had largely affected hospital stay of 
patients indirectly influencing economic burden on patients. 
ADR are often poorly identified and reported in day to day 
medical practice. As we collect more and more information 
about ADRs, we need an active surveillance system regarding 
identification and reporting of ADRs with antipsychotic 
drugs. Psychiatrist and clinical pharmacist are need to be 
made aware of these potentially fatal adverse effects 
associated with antipsychotic drugs via conduction of 
patients counseling (drugs, disease, doses & side effects), 
quality-based seminars, published medical literature, 
conferences, learning programs and health care camps. 
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